Versant Venture Management, LLC
Q3 2025 13F Holdings
- Locationsan francisco, CA
- Num holdings
9
- Value ($000)
$212,453
- Date Filed 11/10/2025
- Form type13F-HR
- CIK 0001560009
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
L Lenz Therapeutics, Inc. | COMMON STOCK | 52635N103 | $123.76M | 58 % | 2,656,888 | ||
G Monte Rosa Therapeutics, Inc. | COMMON STOCK | 61225M102 | $41.89M | 20 % | 5,652,922 | ||
Jade Biosciences, Inc. | COMMON STOCK | 008064206 | $13.17M | 6 % | 1,525,820 | ||
CRISPR Therapeutics AG | COMMON SHARES | H17182108 | $9.65M | 5 % | 148,831 | ||
S Skye Bioscience, Inc. | COMMON STOCK | 83086J200 | $7.89M | 4 % | 2,007,704 | ||
C Contineum Therapeutics, Inc. | COMMON STOCK | 21217B100 | $6.38M | 3 % | 542,628 | ||
R Repare Therapeutics, Inc. | COMMON STOCK | 760273102 | $4.66M | 2 % | 2,646,657 | ||
T Tempest Therapeutics, Inc. | COMMON STOCK | 87978U108 | $2.77M | 1 % | 269,772 | ||
A Adverum Biotechnologies, Inc. | COMMON STOCK | 00773U108 | $2.30M | 1 % | 506,821 |
Rows Per Page
10
- 10
- 50
- 100